BFRI — Q2 2026 Financial Report Analysis

Biofrontera came within about half a million dollars of breaking even in the second quarter of 2026. Revenue rose 32.9% to $12.0 million and the operating loss shrank from $5.1 million to $0.5 million. Two things drove most of that. First, a cheaper supply deal for its only drug, Ameluz, which took gross margin from 71% to 80%. Second, a one-time burst of orders: customers bought early before a patent ruling blocked one of the company's lamps on July 7. Without those early orders the quarter still shows real progress, but it is less dramatic. The company still has only $4.7 million of cash and says in the filing that there is "substantial doubt" it can keep operating for the next 12 months without more funding.

Biofrontera sells one product system in the US. Ameluz is a prescription gel that is applied to the skin and then activated with a red lamp (photodynamic therapy, or PDT). It is used to treat actinic keratosis, which are pre-cancerous skin lesions. Dermatology offices buy the gel and the company's RhodoLED lamps.

At a glance

• Revenue $12.0M, +32.9%. About $1.9 million of the $3.0 million increase came from customers ordering early ahead of the lamp ban, according to the company. That revenue was borrowed from later quarters, not new demand.
• Gross margin 79.9%, up from 70.7%. This change is structural and should last. Since the October 2025 deal with its former parent, Biofrontera AG, the company pays production cost plus a 12% earnout on Ameluz sales, instead of a transfer price of 25% of net revenue.
• Cash $4.7M, going-concern warning. First-half operating cash burn fell to $1.7 million from $7.2 million. Even so, management says current resources are not enough to fund the business for the next 12 months.

The numbers

Gross margin here is revenue minus cost of revenues (product cost plus logistics), as a share of revenue. Operating margin is the share of revenue left after all operating costs, before interest and tax. "n/m" means a percentage change is not meaningful when both periods are losses.

For the first half of 2026, revenue was $22.1 million, up 25.4%. The net loss was $5.4 million, compared with $9.5 million a year earlier, and the loss per share was $0.44, compared with $1.05.

What drove the quarter

Revenue. The 10-Q breaks the $3.0 million increase into three parts. Unit volume of Ameluz rose 30.0%, adding $2.6 million. Of that, "approximately $1.9 million" came from "accelerated order timing from certain customer accounts in anticipation of supply restrictions resulting from the ITC Matter." The rest of the volume gain, about $0.7 million, the company attributes to better sales execution. A list-price increase from the fourth quarter of 2025 added $0.3 million.

Cost of the product. Cost of revenues from the related party (what Biofrontera pays Biofrontera AG) fell to $2.2 million from $2.4 million, even though volume rose 30%. Under the old license, Biofrontera paid 25% of net revenue for the product. Under the new deal it pays direct cost plus a 12% earnout on Ameluz sales. That earnout rises to 15% of all Ameluz revenue in any year US Ameluz sales exceed $65 million. The change in cost structure is the main reason gross profit rose $3.2 million year on year.

Operating expenses. Selling, general and administrative (SG&A) expense fell $0.9 million to $9.6 million. General and administrative costs fell $2.1 million, "mainly from lower litigation-related legal fees", because legal activity peaked in Q2 2025. That saving was partly offset by $0.6 million more spending on the sales force and sales support. Another $0.5 million went to manufacturing, regulatory and product-affairs work that Biofrontera took over from its former parent in 2026. Research and development (R&D) spending halved to $0.4 million because clinical trials finished early. That figure includes a small credit from reversing accrued costs for the acne trial.

What the headline numbers hide

• The early orders flatter the quarter by more than a million dollars of profit. Take out the $1.9 million of pulled-forward revenue at the quarter's roughly 80% gross margin. On that basis, Q2 revenue would have been about $10.1 million, up roughly 12%, and the operating loss would have been about $2.0 million instead of $0.5 million. That is our estimate, not a company figure. Those orders are expected to come out of the second half. Management says the shift affects "the timing of orders rather than total demand" and should not hurt its full-year 2026 revenue goals. The company has not published a number for those goals.
• The underlying trend still improved. Q1 2026 revenue was $10.1 million, up 17.4% from $8.6 million in Q1 2025 (derived from the six-month and Q2 figures). Q1 had no lamp-ban effect. The structural gain in gross margin shows up in both quarters.
• Cash burn fell, with help from unpaid bills. First-half operating cash outflow was $1.7 million, compared with $7.2 million a year earlier. That figure absorbed a $3.7 million paydown of money owed to Biofrontera AG. It was helped by bills owed to other suppliers more than doubling, from $1.9 million to $4.3 million, and by receivables falling $1.7 million after the seasonally strong fourth quarter. Paying suppliers later frees cash for a while, but cannot be repeated indefinitely.
• Adjusted vs GAAP. The gap is small this quarter. Adjusted EBITDA was -$0.2 million and the GAAP net loss was -$0.6 million. Adjusted EBITDA excludes interest, tax, depreciation, $0.26 million of stock-based compensation and a small gain on warrant revaluation. For the half year, it also excludes $0.45 million of patent-remediation charges.
• Per-share figures benefit from more shares. The weighted-average share count rose 38% to 12.9 million, mainly from conversions of preferred stock. More shares spread the loss more thinly. At last year's share count, Q2's loss would still have been only about $0.06 a share, so almost all of the improvement is operational. More dilution is likely. Shares outstanding rose to 14.2 million by June 30. Another 552,483 shares were issued on July 8 from preferred-stock conversions. The $4.2 million of secured convertible notes, which pay 10% interest in additional notes, can convert at $0.78 a share and mature in November 2027.
• Going-concern language. The 10-Q says "the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months" and that this raises "substantial doubt" about the company's ability to continue as a going concern. The plan is to keep growing Ameluz sales while controlling costs, draw on a working-capital credit line, collect a $1.0 million milestone payment expected in December 2026 from the 2025 sale of the Xepi product, and raise equity or debt "if necessary."

The lamp ruling

On May 6, 2026 the US International Trade Commission (ITC) found that Biofrontera's larger RhodoLED XL lamp infringes patents held by Sun Pharma. The ITC banned the lamp's import and sale, and also banned selling Ameluz for use with that lamp. The ban took effect on July 7 after a 60-day presidential review. The standard BF-RhodoLED lamp is not affected. Management says "the substantial majority" of its installed lamp base is unaffected, but the 10-Q does not give the share of sales tied to the XL.

The company booked a $0.5 million remediation charge in the first half. It asked US Customs on June 4 to rule that a redesigned XL falls outside the ban, and expects an answer in September or October 2026. Its patent-office challenge also suffered a setback. On July 29 the USPTO Director vacated a February ruling that had found all challenged claims of one of Sun's two patents unpatentable. Biofrontera says it may appeal both decisions.

Takeaway: The cheaper Ameluz supply deal is a lasting improvement: it added about nine points of gross margin and does not depend on any one quarter's sales. The near-breakeven Q2, however, was partly a one-time stock-up ahead of the lamp ban, and the company has only $4.7 million of cash plus a going-concern warning. Q3 and Q4 will show whether underlying growth of roughly 12-17% can cover costs without new outside funding.

Did last time's read hold up?

This is our first published analysis of Biofrontera, so there is no earlier outlook to check against.

What to watch next

• Q3 2026 results (10-Q expected around mid-November). Q3 faces three pressures at once. Summer is the weakest season for PDT, since lamp treatments happen mostly in winter. Some customers already bought in Q2. And the XL lamp has been off the market since July 7. A sharp drop in revenue from the previous quarter would not by itself mean demand is breaking down. A Q3 well below last year's level would be a bad sign.
• The September 14 FDA approval. After the quarter ended, the FDA approved Ameluz with the BF-RhodoLED lamp for superficial basal cell carcinoma, a common skin cancer. That makes Ameluz the first PDT approved in the US to treat a skin cancer. In the Phase 3 trial, 66% of treated patients achieved complete clearance of the main lesion, compared with 5% on placebo. The company plans a launch from late Q4 2026 through Q1 2027 using its existing sales force and the lamps already in clinics. It cites an estimated 540,000-720,000 US cases a year. This is the clearest source of new revenue, but it will not show up before 2027.
• Funding. With $4.7 million of cash, the company may need new funding. Any equity or convertible financing, or a draw on the credit line, matters as much for shareholders as the sales numbers. The same goes for whether management meets its stated aim of reaching cash-flow breakeven in 2026.
• The Customs ruling on the redesigned XL lamp, expected in September or October 2026, and any appeal of the ITC and USPTO decisions.

Our view: the cost reset makes breakeven plausible on revenue of roughly $12-13 million a quarter. Biofrontera reached that level in Q2 only with help from early orders. The second half is seasonally weaker, so 2026 cash-flow breakeven looks hard to reach, and the sBCC launch probably matters more for 2027 than for this year.